AMLX — Amylyx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1658551 ·
Last close
$27.52
Market Cap
$3.54B
52W High
$41.14
52W Low
$10.83
ADV30
1,421,494
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -49,658,000 | -45,489,000 | 786,795,000 | 240,095,000 | 33,059,000 |
| Jun 2026 | 0 | — | -45,693,000 | -43,423,000 | 264,564,000 | 49,326,000 | 25,397,000 |
| Mar 2026 | 0 | 0 | -43,779,000 | -41,284,000 | 293,603,000 | 229,136,000 | 20,442,000 |
| Dec 2025 | 0 | 0 | -36,605,000 | -32,999,000 | 332,645,000 | 226,651,000 | 27,386,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-129,883,000
Investing CF
$-409,732,000
Financing CF
$554,646,000
CapEx
$-152,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.44
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-881,623,000
Inventory
—
Receivables
$88,000
ST Investments
$528,037,000
EBIT TTM
$-175,735,000
Pretax Income TTM
$-163,149,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -153,291,000 | -144,735,000 | 332,645,000 | 27,386,000 | 305,259,000 | -123,343,000 |
| Dec 2024 | 87,371,000 | -255,677,000 | -301,743,000 | 193,634,000 | 28,869,000 | 164,765,000 | -167,647,000 |
| Dec 2023 | 380,786,000 | 38,802,000 | 49,271,000 | 517,454,000 | 84,022,000 | 433,432,000 | 11,919,000 |
| Dec 2022 | 22,230,000 | -201,341,000 | -198,375,000 | 391,453,000 | 50,846,000 | 340,607,000 | -179,871,000 |
TTM Snapshot
Revenues TTM
$4,893,000
NetIncome TTM
$-152,092,000
OpCashFlow TTM
—
Assets (Latest)
$264,564,000
Forward EPS
$-1.09
Max Pain — expiry 2027-12-17
max pain strike: $20.00 · spot: $26.62 · call oi: 2,244 · put oi: 1,136Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PBLS | Parabilis Medicines, Inc. | $3.49B | $28.25 | — |
| IRON | Disc Medicine, Inc. | $3.49B | $76.57 | — |
| ABCL | AbCellera Biologics Inc. | $3.60B | $11.03 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.46B | $27.33 | — |
| ELVN | Enliven Therapeutics, Inc. | $3.45B | $46.85 | — |
News headlines (Yahoo Finance, 1h cache)
Amylyx Pharmaceuticals Presents Results from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
2026-11-14 17:00 · Yahoo
Why Amylyx Pharmaceuticals Stock Is Up 6.8% And What's Next
2026-11-08 04:27 · Yahoo
Amylyx Pharmaceuticals (AMLX) Stock Looks Pricey After Positive Phase 3 Results
2026-11-07 23:12 · Yahoo
Amylyx Pharmaceuticals (AMLX) Posts Positive Phase 3 Data, Is The 30% Discount Justified?
2026-11-07 21:15 · Yahoo
Amylyx Pharmaceuticals Inc (AMLX) Q3 2026 Earnings Call Highlights: $768 Million Cash Position ...
2026-11-07 19:06 · Yahoo
Amylyx Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-05 23:52 · Yahoo
Amylyx (AMLX) Q3 2026 Earnings Call Transcript
2026-11-05 19:16 · Yahoo
Amylyx Pharmaceuticals Q3 Earnings Call Highlights
2026-11-05 17:14 · Yahoo
Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-05 12:00 · Yahoo
Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts
2026-11-04 14:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.